Merck suffers a setback over Keytruda formulation in Germany
In a setback for Merck, a German courtroom issued a preliminary injunction that stops the corporate from distributing a brand new subcutaneous formulation of Keytruda in Germany. The ruling got here as a part of a widening patent infringement dispute with Halozyme Therapeutics over the bestselling most cancers therapy.
The Munich Regional Court docket determined that Merck’s formulation would infringe on a patent held by Halozyme in Europe and so Merck is required to halt its launch for Keytruda SC in Germany. Sufferers requiring Keytruda will nonetheless have entry to the prevailing intravenous model, which isn’t affected by the patent dispute or courtroom order.
At subject are sure enzymes known as Mdase that Halozyme developed to allow the administration of medicine by injection and which have fashioned the premise for a broader patent dispute between the businesses on either side of the Atlantic.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
